Compare AbbVie Inc (ABBV) vs Fubotv Inc (FUBO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Fubotv Inc — how do they compare? AbbVie Inc trades at $248.77 (market cap $441.94B), while Fubotv Inc trades at $9.6 (market cap $1.06B). The key difference: AbbVie Inc is far larger — about 416.9× Fubotv Inc's market cap, and AbbVie Inc pays a 2.77% dividend while Fubotv Inc pays none. Which is the better fit depends on your goals.
| ABBV | FUBO | |
|---|---|---|
Market Cap | $441.94B | $1.06B |
Sector | Health | Technology |
52-Week High | $263.58 | $54.72 |
52-Week Low | $197.38 | $8.09 |
Enterprise Value | $506.19B | $1.23B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $249.94, up 0.82% with strong technical momentum and bullish moving averages. The company demonstrates solid fundamentals with $61.16B revenue in 2025 and consistent earnings beats, though net margins have compressed from 20.4% in 2022 to 6.9%. Recent positive Phase 2 data for ELAHERE in ovarian cancer and institutional accumulation signal confidence. Technical indicators show support at $248 and resistance at $251, with the stock trading near analyst consensus targets.
Outlook remains positive with 70.7% analyst buy ratings and $278.69 price target, representing 11.5% upside. Key opportunities include immunology growth from Skyrizi/Rinvoq and pipeline advancements. Risks include patent cliffs in the 2030s, debt levels at 50.4% of assets, and margin pressure from competitive and pricing headwinds. The dividend yield and earnings recovery in 2026 forecast support the bullish case.
FUBO trades at $9.45, up 0.96% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q3 2026 revenue of $1.48 billion, beating expectations, and raised its full-year adjusted EBITDA outlook to $90–$100 million. Valuation ratios appear attractive with a P/E of 2.53 and P/S of 0.19, while recent leadership changes include the appointment of former Disney executive Alisa Bowen as CEO.
The outlook is positive as FUBO shows improving financials and strategic partnerships, but risks include persistent net losses and high debt. Analyst consensus is a Buy with a $15.33 price target, suggesting significant upside potential if profitability goals are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Fubotv Inc
FuboTV Inc is a sports-first, live TV streaming company, offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, fuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. The company offer subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality best suited to their preferences. The operating segments of the group are Streaming and Online wagering, of which a majority of revenue is derived from the Streaming segment. It has a business presence in the U.S. and other international countries.
Read more on FUBO →
